Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 Years in a state mental health care system

Journal of Clinical Psychiatry

Volumn 59, Issue 4, 1998, Pages 189-194

  Reid, William H ^a,b   Mason, Mark ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; COST CONTROL; DRUG USE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH CARE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0031957435     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0408     Document Type: Article

References (24)

1. Martin P. Medical economic impact of schizophrenia. Encephale 1995;21(special section 3):67-73
2. Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, eds. Handbook of Mental Health Economics, vol 1: Schizophrenia. Chichester, England: John Wiley & Sons Ltd; 1996
3. Revicki DA, Luce BR, Wechsler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854
4. Reid WH. Schizophrenia, modern treatment, and the economics of care. Rev Contemp Pharmacother 1995;6:209-215
5. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-264
6. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
7. Chow EW, Collins EJ, Nuttall SE, et al. Clinical use of clozapine in a major urban setting: one year experience. J Psychiatry Neurosci 1995;20: 133-140
8. Ebrahim GU, Gibler B, Gacono CB, et al. Patient response to clozapine in a forensic psychiatric hospital. Hosp Community Psychiatry 1994;45: 271-273
9. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. BrJ Psychiatry 1992;17(5, suppl):41-45
10. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
11. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994:55(9, suppl B):161-165
12. Neuhalfen EA, Kaplan A. Are you missing anything? recent psychotropics available in Europe, but not in the United States. Psychiatric Times, March 1994:34
13. Wilson WH, Claussen AM. 18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. Psychiatr Serv 1995;46: 386-389
14. Chiles JA, Davidson P, McBride D. Effects of clozapine on the use of seclusion and restraint at a state hospital. Hosp Community Psychiatry 1994: 45:269-271
15. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
16. Gury C, Dechelette N, Gayral P. Leponex: experience of the hospital pharmacist. Encephale 1995;21(special section 3):61-65
17. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42
18. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995;92:199-201
19. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638
20. Morris S, Hogan T, McGuire A. The cost-effectiveness of clozapine: a survey of the literature. Clin Drug Invest. In press
21. Essock SM, Hargreaves WA, Dohm FA, et al. Clozapine eligibility among state hospital patients. Schizophr Bull 1996;22:15-25
22. Tyrer P, Morgan J, Van Horn E, et al. A randomised controlled study of close monitoring of vulnerable psychiatric patients. Lancet 1995;345: 756-759
23. Walker AM, Lanza LL, Arellano A, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
24. Reid WH. The treatment of psychosis: resetting the drug cost "thermostat." J Clin Psychiatry 1994;55(9, suppl B):166-168